Trailblazing shearer Margaret Gould died from burns, Coroner warns of risks to elderly living alone
Fire and Emergency New Zealand data showed that around 55% of fire deaths in New Zealand over the past five years were of people aged 65 or over, and many of those people were living alone.
Tenant raced to her aid
Gould lived in the rear residence of a property she owned in the Marlborough township of Renwick, near Blenheim.
The property had another home in front, which she rented out.
It was the afternoon of December 10 last year when her tenant's young son heard a 'beeping sound' coming from Gould's house.
The home had smoke alarms in the hallway and lounge which were activated at the time of the fire, an investigation found.
The tenant ran over and saw black smoke coming from Gould's kitchen.
She went inside and found her slumped over the coal range with her body and clothing on fire.
The opinion of a fire investigator was that while Gould had been cooking and stoking the fire, she either received radiant heat long enough that her clothing ignited, or her clothes had come into contact with the open flame from the fire.
Specialist investigator Scott Randall said it was also possible that Gould's clothing had been set alight by an ember falling from the range.
The neighbour had noticed a log sticking out of the firebox, which was open.
She extinguished the fire, doused Gould in water, and waited until an ambulance arrived.
Emergency medical help was given at the scene before Gould was flown to Hutt Hospital, where she died from severe burns to much of her body in the early hours of the following day.
Pathologist Mark Tullett identified 46% full-thickness burns to her entire body which were 'extremely severe and life threatening'.
Family member 'concerned'
Coroner Wilton said Gould had visited her doctor four months before her death for a sprain injury to her arm and shoulder from lifting a heavy pot of water.
The pain was limiting her function, and she was referred to an orthopaedic surgeon.
The GP practice also advised that a family member had called concerned about Gould's welfare. Home help was discussed, but she voiced her concerns about that.
'Ms Gould was independent and did not like people in her home,' Coroner Wilton said.
He made no recommendations, but endorsed a list of fire safety messages and advice aimed at raising fire safety awareness in the homes of all New Zealanders, and particularly older New Zealanders.
Fire and Emergency NZ encouraged family members and others who visited older people's homes to check for general fire safety.
Fire safety checks should include making a workable escape plan, checking for fire risks associated with cooking and heating and checking for working smoke alarms.
Fire and Emergency NZ also offered to undertake free home fire safety visits to those who required it.
Coroner Wilton 'strongly encouraged' all New Zealanders, and particularly those older, to make use of the 'free and excellent' fire prevention service.
'Celebrity shearer' well known in Marlborough
Gould, a former 'celebrity shearer', was born Margaret Hebberd on December 29, 1930, and died weeks short of her 94th birthday.
She was remembered in death notices with love, laughter and for the stories and wisdom she shared.
Marlborough freelance journalist Jo Grigg, whose profile on Gould featured in rural online magazine CountryWide not long before her death, described her as possibly one of the first female blade shearers in New Zealand.
Margaret Gould (nee Hebberd) (left), and her sister Jean Hebberd shearing at Sydney Airport 1962. Photo / Jo Grigg CountryWide Media
Grigg wrote that Gould was one of nine siblings raised on the family farm at Onahau Bay in Marlborough's Queen Charlotte Sound. When her father, Joseph Hebbard, died in 1942, Margaret was 13. She and her brothers and sisters had no choice but to shear the flock themselves.
'It was the war and there were no shearers around.'
She could blade-shear up to 102 sheep a day, Grigg wrote.
Her sisters, Jean and Gwen, also became competent blade shearers.
Grigg wrote that Margaret and Jean, who became well known in Marlborough, went on to compete at the Golden Shears (blade class) at the inaugural competition in 1961, and were invited to shear at events in Australia, making them perhaps the first female 'celebrity shearers'.
Once, they were asked by the David Jones department store to do a shearing demonstration on a stage at the top of the Sydney store, where the sheep were sent up in the lift, Grigg wrote.
The sisters were also asked to shear sheep on floats at gala days and at garden parties.
Margaret Hebberd, as she was then, scored her first paid job shearing on a farm near Ward, South Marlborough, the day she turned 15.
She married in 1971 and, in the 1980s, moved to Renwick.
Tracy Neal is a Nelson-based Open Justice reporter at NZME. She was previously RNZ's regional reporter in Nelson-Marlborough and has covered general news, including court and local government for the Nelson Mail.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
6 hours ago
- Scoop
Medsafe Consents Improve Year On Year, Again
Associate Minister of Health Annual performance statistics released today show Medsafe following my direction and approving new medicines faster than last year, which was faster than the year before, and there is more to come with the Rule of Two and AI, Associate Health Minister David Seymour says. 'New Zealanders need a smarter, more efficient government which gets things done, enabling them to live better lives,' Mr Seymour says. 'Faster access to medicines matters to patients. For many New Zealanders, pharmaceuticals are life or death, or the difference between a life of pain and suffering or living freely.' Medsafe completed its evaluation for innovative medicines 59 working days faster than last year. This is on top of the 55 days reduction in 2023/24. Generic medicines decisions were 64 days faster than last year, on top of the 45 days reduction in 2023/24. Medsafe has again met 100% timeframes for over-the-counter medicines, providing certainty for pharmaceutical companies. 'Assessment timeframes for most categories of medicine are now similar to the timeframes required in Australia. We often use compare ourselves to Australia, and in this area we have caught up,' says Mr Seymour. 'The abbreviated pathway is also reducing timeframes. It requires Medsafe to work smarter by leveraging work already done by other overseas regulators. About 50 percent of medicines are assessed like this, and in half the time of the full pathway. 'Medsafe will speed up approval processes further. The Medicines Amendment Bill includes the Rule of Two, which will be in operation by early 2026. The Rule of Two requires Medsafe to approve new pharmaceuticals within 30 days of them being approved by at least two overseas regulatory agencies recognised by New Zealand. 'Last year I wanted Medsafe to find more innovative ways to expedite their approval pathways. One way they have done this is by prioritising new innovative medicines and assessing them under urgency because people need them now. 'Some of these included the Bleriplex medicine for people with blood clotting disorders, the blood cancer medicine Omjjaro, Tyruko for multiple sclerosis, and the Wyost injection for weakened bones due to cancer. For Omjjaro, this meant it was able to be approved 131 days faster than the average time last year for new innovative medicines. 'Earlier this year I wrote to Medsafe asking them to find ways that AI could help the process new medicines faster. This is something that they have welcomed and recognise could reduce assessment times. I look forward to working with Medsafe as they explore this. 'We're committed to ensuring that the regulatory system for pharmaceuticals is not unreasonably holding back access. We want it to lead to more Kiwis being able to access the medicines they need to live a fulfilling life, not less.'
Scoop
10 hours ago
- Scoop
Cancer, Measles And Allergic Disease Research Funded In Latest HRC Grants Round
Press Release – Malaghan Institute of Medical Research Director Professor Kjesten Wiig says receiving three major grants from the Health Research Council at a time of heightened funding constraints is significant and recognises the calibre and relevance of the Malaghan Institutes science. The Malaghan Institute has been awarded three Health Research Council grants, totalling $7.4M over five years, to improve cancer immunotherapies, protect vulnerable populations from measles outbreaks and investigate new therapeutic targets for eczema. Director Professor Kjesten Wiig says receiving three major grants from the Health Research Council at a time of heightened funding constraints is significant and recognises the calibre and relevance of the Malaghan Institute's science. 'These investments not only reflect confidence in the Malaghan's research across cancer, allergic and infectious diseases, but also the real-world impact of our work on the health of New Zealanders.' Faster CARs: Overcoming exhaustion to enhance cancer immunotherapies Building on the Malaghan Institute's ground-breaking CAR T-cell programme, the Perret team in the Weinkove Laboratory has recieved a $1.2 million project grant over three years to improve on this life-saving treatment. 'In Aotearoa's first CAR T-cell trial, our novel CAR T-cell therapy has shown promising safety and efficacy in people with relapsed lymphomas,' says Dr Rachel Perret. 'However, a known limitation of CAR T-cell therapies is that in some cases, cancers fail to respond, or relapse. This may be due to exhaustion of CAR T-cells during manufacture or inside the patient, due to a immunosuppressive environment around the tumour.' Cells, like people, can become exhausted if overworked or overstimulated, becoming less and less able to perform. However, unlike people, CAR T-cells can be tweaked to block the genes that signal this exhaustion, allowing them to continue fighting cancer for longer – which should also improve patient outcomes. 'This project will re-engineer CAR T-cells to silence genes linked to exhaustion and re-develop CAR T-cell manufacturing processes to enhance CAR T- cell fitness and shorten manufacturing times,' says Dr Perret. 'We expect the results to be applicable to many cancer types, and to be readily translated for the benefit of New Zealanders within our CAR T-cell clinical trial programme.' Providing equal protection for everyone against measles Herd immunity is how we as a population protect those who are immunocompromised or otherwise unable to get vaccinated (such as very young infants) against potentially life-threatening viruses like measles. When enough of the population are vaccinated (over 95% in the case of measles), this herd immunity effectively prevents viruses from spreading to our most vulnerable whānau. 'While the current measles, mumps and rubella (MMR) vaccine is highly effective at protecting vaccinated individuals against these viruses, current vaccination rates are not high enough to provide this essential herd immunity to protect those who cannot be vaccinated,' says paediatric immunologist Dr Kuang Hsiao from Waipapa Taumata Rau, University of Auckland, who is part of the research team. The MMR vaccine cannot be used in people with severely impaired immune systems and is not recommended in pregnant people. Also, MMR is less effective in infants, so is not routinely recommended before 12 months of age. In addition, Māori and Pacific communities are overrepresented among these vulnerable groups. For these populations, alternate protective options are required to prevent a measles outbreak. 'Evidence has shown that mRNA-based vaccines can be effective in these vulnerable individuals,' says the Malaghan's Professor Ian Hermans. 'With an international team involving clinicians, immunologists and Māori and Pacific researchers, we will develop an mRNA-based measles vaccine to give to vulnerable individuals in the event of an outbreak.' The research has been awarded an HRC Programme Grant, worth $5M over five years, and will bring together multiple organisations including the Malaghan, representing diverse areas of expertise and combining both fundamental research and public health. 'As part of this work, we will explore with Māori and Pacific communities' perceptions and beliefs about mRNA-based vaccines to support equitable access to the vaccine,' says Dr Hermans. Investigating novel treatment targets for atopic dermatitis Atopic dermatitis, or eczema, is a chronic skin allergic disease that affects a significant proportion of New Zealand's population. The disease can have a significant negative impact on a person's livelihood with symptoms varying from persistent itchiness, redness, dryness and inflammation. Current treatment options are largely immunosuppressants such as corticosteroids, which can cause side effects. While these treatments can help manage symptoms there are currently no effective therapies to prevent the disease from developing and relapsing. At the cellular level, one hallmark of atopic dermatitis is the chronic infiltration and persistence of immune cells called tissue resident memory T-cells. Normally, these cells are vital for protecting the skin from invading pathogens, but for individuals with atopic dermatitis these cells also contribute to the disease by promoting recurring inflammation even after the allergen has been cleared from the skin. The project, which has been awarded $1.2 million over three years, will be led by Dr Sotaro Ochiai, a Senior Research Fellow in the Ronchese Laboratory. The team will focus on better understanding these tissue resident memory T-cells identifying key genes and biological pathways that are essential for the establishment and maintenance of these cells in the skin. 'By understanding these mechanisms, we aim to identify new therapeutic targets to disrupt tissue resident memory T-cell survival or function and improve quality of life for those affected by this persistent and distressing condition,' says Dr Ochiai.
Scoop
2 days ago
- Scoop
Faster, More Accurate Brain Tumour Diagnoses For Kiwis
Minister of Health More than 100 New Zealanders have already benefited from a groundbreaking diagnostic tool that is delivering faster, more accurate brain tumour diagnoses, Health Minister Simeon Brown says. DNA methylation profiling, the international gold standard for diagnosing brain tumours, has been rolled out at Auckland City Hospital over the past year. 'This technology is a game-changer for brain tumour diagnosis in New Zealand. It enables doctors to pinpoint the exact tumour type with greater precision and in less time, meaning patients can start the right treatment sooner,' Mr Brown says. 'Until now, diagnosis was typically made by microscopic examination. In some complex cases, samples were sent overseas for methylation profiling, but that could take up to six weeks. 'Having this cutting-edge capability in New Zealand means more Kiwi patients can access this advanced diagnostic technology locally. Turnaround times are faster, around four weeks, and quicker for urgent cases. 'It also means we can prioritise urgent cases, deliver answers sooner, and give patients and their families greater certainty.' In some recent cases done locally, methylation profiling has significantly altered the initial diagnosis. In others, it has identified rare or unexpected tumour types that may have been missed using traditional methods. The Auckland-based service is one of only three in Australasia, with samples from hospitals around the country also being sent to Auckland for analysis. Along with improving access and outcomes for patients, it is also significantly cheaper than sending samples offshore. 'Delivering faster access to cancer treatment is a key focus for the Government, which is why it is one of our five national health targets. Faster, more accurate diagnosis for brain tumours that may be cancerous is a vital part of that. 'By providing local access to the world's best diagnostic tools, we are improving outcomes for New Zealanders,' Mr Brown says.
